Publication of supplementary prospectus related to Nexam Chemical’s rights issue
The board of directors of Nexam Chemical Holding AB (”Nexam Chemical” or the ”Company”) has prepared a supplementary prospectus (the “Supplementary Prospectus”) to the EU Growth Prospectus that was approved and registered by by the Swedish Financial Supervisory Authority (the “SFSA”) on March 12, 2020 (the “Prospectus”).The Supplementary Prospectus has been prepared since Nexam Chemical, during the subscription period of the ongoing rights issue of units (the “Rights Issue”), has signed a supply agreement with Diab, corresponding to a total sales value of between SEK 100 and 120 millon